1189797-76-9

Upstream product

• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 88145-89-5 6-bromo-1H-quinazoline-2,4-dione 
• 89523-63-7 benzylzinc chloride 
• 174313-65-6 2-(methylsulfanyl)-6-bromo-quinazolin-4(3H)-one 
• 1189797-84-9 9-bromo-2-(4-methylphenyl)-5-(methylsulfanyl)[1,2,4]-triazolo[4,3-c]quinazolin-3(2H)-one 
• 1189797-83-8 6-bromo-2-(methylsulfanyl)-4-(3-nitro-1H-1,2,4-triazol-1-yl)quinazoline 
• 624-31-7 4-tolyl iodide 
• 49681-94-9 6-Methyl-4-oxo-2-thioxo-1,2,3,4-tetrahydrochinazolin 
• 1189797-63-4 9-bromo-2-(4-methylphenyl)-2,6-dihydro[1,2,4]triazolo-[4,3-c]quinazoline-3,5-dione 
• 28493-54-1 benzyltributyltin 

Relevant academic research and scientific papers

TRIAZOLOQUINAZOLINONE SYNTHESIS

The invention relates to an improved process for preparing triazoloquinazolinones of Formula (I), including 9-benzyl-2-(4-methylphenyl)-2,6-dihydro[l,2,4]triazolo[4,3-c]quinazoline-3,5-dione, pharmaceutical compositions comprising the compounds of Formula (I), including 9-benzyl-2-(4- methylphenyl)-2,6-dihydro[l,2,4]triazolo[4,3-c]quinazoline-3,5-dione, prepared by the improved process, and methods of treatment using the compounds of Formula (I), including 9-benzyl-2-(4- methylphenyl)-2,6-dihydro[l,2,4]triazolo[4,3-c]quinazoline-3,5-dione, prepared by the improved process.

Triazoloquinazolinediones as novel high affinity ligands for the benzodiazepine site of GABAA receptors

Based on a pharmacophore model of the benzodiazepine-binding site of GABAA receptors, a series of 2-aryl-2,6-dihydro[1,2,4]triazolo[4,3-c] quinazoline-3,5-diones (structure type I) were designed, synthesized, and identified as high-affinity lig

GABAA RECEPTOR MODULATORS

the resent invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAA receptor modulator.